Elutia Inc. (ELUT) has a MoatMap StockRank of 23/100 based on Quality (25/100), Value (41/100), and Momentum (43/100) factor scores. The current signal is SELL. Elutia Inc. is a micro-cap medical technology company specializing in drug-eluting biomaterials. It is unprofitable, has a weak balance sheet, and lacks the scale or market dominance required for our portfolio.
Elutia Inc. develops and commercializes proprietary biologic drug-eluting matrices and regenerative medicine products. The company's competitive moat is secured by its proprietary CanGaroo envelope platform, which delivers targeted antibiotics to prevent surgical site infections. It is a specialized medical device player focused on the high-margin cardiovascular and reconstructive surgery markets.
| Price | $0.97 |
| Market Cap | $51M |
| P/E (Forward) | -0.95 |
| Price/Book | 1.62 |
| Return on Invested Capital | -49.5% |
| Debt/Equity | 14.24 |
| Gross Margin | 53.7% |
| Operating Margin | -167.9% |
| Revenue Growth | 16.2% |
| Free Cash Flow | $-25M |
Elutia Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).